The content on this site is intended for healthcare professionals only
Research suggests that a new targeted therapy, quizartinib, may be a safe and effective option to treat a subset of patients with treatment-resistant acute myeloid leukaemia (AML), whose leukaemia has the FLT3-ITD mutation.
Quizartinib is the first and only single-agent drug that has produced a clinical benefit in AML patients with this deadly mutation who have failed previous therapy.
The number of patients bridged to a stem cell transplant was very significant. Dr Levis and his colleagues plan on using these encouraging results to design and conduct additional randomized trials that will hopefully lead to the approval of quizartinib to make it accessible to those patients who previously had no hope for a cure.
From an official Press Conference at ASH 2012.
Daratumumab, bortezomib/thalidomide/dexamethasone (D-VTd) and DARA maintenance shows benefit in transplant-eligible NDMM
Treating relapsed multiple myeloma outside of use of T-cell redirected therapies
Isatuximab, plus bortezomib, lenalidomide, and dexamethasone shows improved PFS in frail NDMM patients
Isa-KRd quad regimen in NDMM: MIDAS and CONCEPT studies
Isatuximab in combination with pomalidomide and dexamethasone shows promising efficacy in 2nd line RRMM
ASCO 2024: Two studies report on isatuximab combos in transplant-ineligible patients with newly diagnosed multiple myeloma
Multiple myeloma in a resource constrained setting
Significant clinical benefits observed with revumenib monotherapy in relapsed/refractory KMT2Ar acute leukaemia
Ide-cell enhances health-related quality of life for refractory multiple myeloma
